Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bill Ackman Eyes New Fund to Bet Against Market Complacency
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 



